Bal Pharma Ltd
BALPHARMABal Pharma Ltd
BALPHARMA
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 25.01 | 2.77 | 0.99% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Bal Pharma Limited is engaged in the manufacture and sale of pharmaceutical products. The Company’s business comprises of Active Pharmaceutical Ingredients (API), Finished Formulations, Ayurvedic, Research and Development.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 199.59 | 231.95 | 213.21 | 226.02 | 172.94 | 251.67 | 286.36 | 305.16 | 342.07 | 327.51 | ||||||||||
Raw Materials | 105.26 | 122.58 | 112.48 | 121.58 | 81.23 | 145.90 | 172.42 | 190.64 | 192.82 | 292.79 | ||||||||||
| Power & Fuel Cost | 4.66 | 6.01 | 6.07 | 6.38 | 4.76 | 4.98 | 5.89 | 7.73 | 8.73 | |||||||||||
| Employee Cost | 37.30 | 45.37 | 52.16 | 50.28 | 50.44 | 41.88 | 47.25 | 55.30 | 60.38 | |||||||||||
| Selling & Administrative Expenses | 27.42 | 36.48 | 26.09 | 25.77 | 18.51 | 16.24 | 23.28 | 26.88 | 31.57 | |||||||||||
| Operating & Other expenses | 8.83 | 3.66 | -2.66 | 3.31 | 11.12 | 16.89 | 8.40 | -1.58 | 14.02 | |||||||||||
EBITDA | 16.12 | 17.85 | 19.07 | 18.70 | 6.88 | 25.78 | 29.12 | 26.19 | 34.55 | 34.72 | ||||||||||
| Depreciation/Amortization | 7.01 | 6.49 | 6.77 | 6.15 | 7.68 | 9.52 | 9.04 | 9.13 | 10.07 | 10.03 | ||||||||||
| PBIT | 9.11 | 11.36 | 12.30 | 12.55 | -0.80 | 16.26 | 20.08 | 17.06 | 24.48 | 24.69 | ||||||||||
| Interest & Other Items | 6.48 | 8.49 | 9.41 | 12.74 | 12.73 | 12.16 | 10.91 | 12.31 | 15.44 | 15.69 | ||||||||||
| PBT | 2.63 | 2.87 | 2.89 | -0.19 | -13.53 | 4.10 | 9.17 | 4.75 | 9.04 | 9.00 | ||||||||||
| Taxes & Other Items | 1.24 | 1.12 | 0.09 | -3.99 | -1.31 | -0.64 | 3.57 | 2.18 | 1.66 | 1.33 | ||||||||||
| Net Income | 1.39 | 1.75 | 2.80 | 3.80 | -12.22 | 4.74 | 5.60 | 2.57 | 7.38 | 7.67 | ||||||||||
| EPS | 1.08 | 1.29 | 1.98 | 2.68 | -8.62 | 3.27 | 3.78 | 1.68 | 4.69 | 4.85 | ||||||||||
| DPS | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.20 | 1.20 | ||||||||||
| Payout ratio | 0.93 | 0.77 | 0.51 | 0.37 | 0.00 | 0.31 | 0.26 | 0.59 | 0.26 | 0.25 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Bal Pharma Ltd | 25.99 | 2.77 | 0.99% |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare BALPHARMA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 17, 2024
Dividend/Share
₹1.20
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateSep 18, 2023
Dividend/Share
₹1.00
Ex DateEx Date
Sep 18, 2023
Cash Dividend
Ex DateEx DateSep 13, 2022
Dividend/Share
₹1.00
Ex DateEx Date
Sep 13, 2022
Cash Dividend
Ex DateEx DateSep 16, 2021
Dividend/Share
₹1.00
Ex DateEx Date
Sep 16, 2021
Cash Dividend
Ex DateEx DateSep 17, 2019
Dividend/Share
₹1.00
Ex DateEx Date
Sep 17, 2019
Net profit of Bal Pharma rose 9.47% to Rs 1.04 crore in the quarter ended September 2024 as against Rs 0.95 crore during the previous quarter ended September 2023. Sales declined 20.37% to Rs 73.69 crore in the quarter ended September 2024 as against Rs 92.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales73.6992.54 -20 OPM %10.448.32 - PBDT3.844.02 -4 PBT1.361.60 -15 NP1.040.95 9 Powered by Capital Market - Live
Bal Pharma will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Bal Pharma will hold a meeting of the Board of Directors of the Company on 9 September 2024.Powered by Capital Market - Live
Bal Pharma announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live
Net profit of Bal Pharma rose 225.00% to Rs 0.26 crore in the quarter ended June 2024 as against Rs 0.08 crore during the previous quarter ended June 2023. Sales rose 5.64% to Rs 74.36 crore in the quarter ended June 2024 as against Rs 70.39 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales74.3670.39 6 OPM %8.699.15 - PBDT3.052.96 3 PBT0.620.43 44 NP0.260.08 225 Powered by Capital Market - Live
Bal Pharma will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live
Bal Pharma Consolidated March 2023 Net Sales at Rs 82.45 crore, up 11.35% Y-o-Y
Bal Pharma Consolidated December 2022 Net Sales at Rs 76.62 crore, up 10.77% Y-o-Y
Balkrishna Paper Mills Ltd leads gainers in ‘B’ group
Yaari Digital Integrated Services Ltd leads gainers in ‘B’ group
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 8.64%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.1% to 0.09%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 14.2%, vs industry avg of 15.27%